Dermatological conditions

Make sunscreen protection rating clearer, urges pharmacist organisation

The Royal Pharmaceutical Society calls on sunscreen manufacturers to adopt single sun protection rating after survey reveals public confusion.…

Trauma to joints can increase risk of psoriatic arthritis

Patients with psoriasis who experience trauma to the joints or bones are up to 50% more likely to go on to develop psoriatic arthritis, finds new research.…

Warts and verrucas: assessment and treatment

Lesions caused by human papilloma virus often do not require treatment, but need to be assessed to rule out more serious conditions.…

Onion skin cells make an effective muscle actuator

Treating onion skin cells with sulphuric acid and gold allow them to be used as a muscle simulator.…

Boots’ sunscreen lotion fails sun protection test, says Which?

Two sunscreens, including one manufactured by Boots, have failed sun protection tests, according to research conducted by the UK consumer watchdog Which? …

Burns: assessment and treatment

Quick action is required with burns to minimise tissue damage and prevent infection.…

Unnecessary visits to A&E will continue to occur

I wish to comment on Adam Pattison Rathbone’s blog ‘Could pharmacists be part of the A&E problem?’ ( The Pharmaceutical Journal 2015;294:385). I would like to share a recent experience of mine that illustrates how the pressures on out-of-hour GP services and a…

Tildrakizumab shows promise as psoriasis treatment

Merck reports in a phase I trial that its new monoclonal antibody, tildrakizumab, reduces psoriasis symptoms.…

First-in-class oral drug approved for psoriasis conditions in Europe

The European Commission has authorised apremilast (Celgene’s Otezla), a first-in-class oral drug for the treatment of chronic plaque psoriasis and psoriatic arthritis in patients who have failed first-line systemic therapies.…